Calamos Advisors LLC Boosts Stake in Edwards Lifesciences Co. (NYSE:EW)

Calamos Advisors LLC grew its stake in Edwards Lifesciences Co. (NYSE:EW) by 0.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 167,950 shares of the medical research company’s stock after acquiring an additional 228 shares during the quarter. Calamos Advisors LLC’s holdings in Edwards Lifesciences were worth $12,433,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in EW. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences in the third quarter worth $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences during the 3rd quarter worth $32,000. Avior Wealth Management LLC increased its position in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares in the last quarter. Roble Belko & Company Inc purchased a new stake in Edwards Lifesciences in the fourth quarter valued at about $46,000. Finally, JFS Wealth Advisors LLC boosted its holdings in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research analyst reports. Robert W. Baird decreased their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $75.00 to $90.00 in a report on Thursday, January 30th. The Goldman Sachs Group raised their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Piper Sandler decreased their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $79.19.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 8,000 shares of company stock worth $547,430 in the last ninety days. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Stock Performance

EW opened at $71.33 on Wednesday. The firm has a market capitalization of $42.07 billion, a PE ratio of 10.29, a PEG ratio of 3.72 and a beta of 1.11. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The firm’s 50-day moving average price is $72.49 and its 200 day moving average price is $69.63.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.